18559-94-9
18559-94-9
Chemical Structure
Salbutamol
Synonym(s): Albuterol; AH-3365
- CAS No.: 18559-94-9
- Formula:C13H21NO3
- Molecular Weight:239.31
IUPAC Name: 4-(2-(tert-butylamino)-1-hydroxyethyl)-2-(hydroxymethyl)phenol
InChIKey: NDAUXUAQIAJITI-UHFFFAOYSA-N
SMILES: OC(CNC(C)(C)C)C1=CC=C(O)C(CO)=C1
Biological Activity: Salbutamol (Albuterol) is an orally active short-acting β2-adrenergic receptor agonist. Salbutamol promotes tumorigenesis in gastric cancer cells through the β2-AR/ERK/EMT pathway. Salbutamol can relax bronchial smooth muscle and is used to study bronchospasm induced by asthma and chronic obstructive pulmonary disease[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Salbutamol | 99.53% | Salbutamol (Albuterol) is an orally active short-acting β2-adrenergic receptor agonist. Salbutamol promotes tumorigenesis in gastric cancer cells through the β2-AR/ERK/EMT pathway. Salbutamol can relax bronchial smooth muscle and is used to study bronchospasm induced by asthma and chronic obstructive pulmonary disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Salbutamol (Standard) | 99.91% | Salbutamol (Standard) is the analytical standard of Salbutamol. This product is intended for research and analytical applications. Salbutamol (Albuterol) is a short-acting beta-2 adrenergic receptor agonist with oral activity. Salbutamol promotes tumorigenesis of gastric cancer cells through the β2-AR/ERK/EMT pathway. Salbutamol is used to study bronchospasms caused by asthma and chronic obstructive pulmonary disease (COPD). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Salbutamol-d3 | 98.59% | Salbutamol-d3 (Albuterol-d3) is the deuterium labeled Salbutamol (HY-B1037). Salbutamol (Albuterol) is an orally active short-acting β2-adrenergic receptor agonist. Salbutamol promotes tumorigenesis in gastric cancer cells through the β2-AR/ERK/EMT pathway. Salbutamol can relax bronchial smooth muscle and is used to study bronchospasm induced by asthma and chronic obstructive pulmonary disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Salbutamol-d9 acetate | 99.48% | Salbutamol-d9 (Albuterol-d9) acetate is the deuterium labeled Salbutamol (HY-B1037). Salbutamol (Albuterol) is an orally active short-acting β2-adrenergic receptor agonist. Salbutamol promotes tumorigenesis in gastric cancer cells through the β2-AR/ERK/EMT pathway. Salbutamol can relax bronchial smooth muscle and is used to study bronchospasm induced by asthma and chronic obstructive pulmonary disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Salbutamol-d4 | Salbutamol-d4 (Albuterol-d4; AH-3365-d4) is the deuterium labeled Salbutamol (HY-B1037). Salbutamol (Albuterol) is a short-acting beta-2 adrenergic receptor agonist with oral activity. Salbutamol promotes tumorigenesis of gastric cancer cells through the β2-AR/ERK/EMT pathway. Salbutamol is used to study bronchospasms caused by asthma and chronic obstructive pulmonary disease (COPD). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Salbutamol-d9 | 98.00% | Salbutamol-d9 (Albuterol-d9) is the deuterium labeled Salbutamol (HY-B1037). Salbutamol (Albuterol) is an orally active short-acting β2-adrenergic receptor agonist. Salbutamol promotes tumorigenesis in gastric cancer cells through the β2-AR/ERK/EMT pathway. Salbutamol can relax bronchial smooth muscle and is used to study bronchospasm induced by asthma and chronic obstructive pulmonary disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Lu Y, et al. Chronic stress model simulated by salbutamol promotes tumorigenesis of gastric cancer cells through β2-AR/ERK/EMT pathway. J Cancer. 2022 Jan 1;13(2):401-412. [Content Brief]
- [2]. Hong YP, et al. Effects of Castanospermine on Inflammatory Response in a Rat Model of Experimental Severe Acute Pancreatitis. Arch Med Res. 2016 Aug;47(6):436-445. [Content Brief]
